OrganOx为其器官技术平台获得1.42亿美元股权融资-动脉网

OrganOx secures $142M equity financing for organ technology platform

MobiHealthNews 等信源发布 2025-02-28 22:36



可切换为仅中文







Photo:

照片：

Hero Images Inc.

英雄图片公司

/Getty Images

/盖蒂图片社

Commercial stage organ technology company OrganOx announced it completed a $142 million primary and secondary equity financing.

商业阶段器官技术公司OrganOx宣布已完成1.42亿美元的一级和二级股权融资。

HealthQuest Capital

健康探索资本

led the oversubscribed round with participation from BGF and Lauxera Capital Partners and new investors

领投了超额认购的一轮融资，BGF和Lauxera Capital Partners以及新投资者参与其中

Sofina

索菲娜

, Soleus Capital and Avidity Partners.

，比目鱼资本（Soleus Capital）和阿维迪蒂合伙人（Avidity Partners）。

Existing investors include the

现有投资者包括

University of Oxford

牛津大学

, Technikos, the Oxford Technology and Innovations Fund, and Longwall Ventures.

，Technikos、牛津技术和创新基金以及Longwall Ventures。

WHAT IT DOES

它有什么作用

OrganOx is a commercial stage organ technology company that came out of the University of Oxford in 2008.

OrganOx是一家商业阶段的器官技术公司，于2008年从牛津大学分离出来。

The company develops technologies aimed at improving outcomes for patients with acute or chronic organ failure. The OrganOx

公司开发旨在改善急性或慢性器官衰竭患者预后的技术。OrganOx

metra is a normothermic machine perfusion platform approved in the U.S., Europe, Canada and Australia.

metra 是一个在美国、欧洲、加拿大和澳大利亚获批的常温机械灌注平台。

OrganOx is also working on an investigational metra

OrganOx 也在研究一种试验性的 metra

technology for kidney transplants, which will be undergoing clinical trials in the U.S. shortly.

肾移植技术，该技术将很快在美国进行临床试验。

The company will use the funds to accelerate growth opportunities for its metra platform technology.

公司将利用这笔资金加速其metra平台技术的增长机会。

'Organ disease and failure represent a large unmet need in healthcare and we are excited to partner with HealthQuest Capital and the outstanding investor syndicate to work together to improve patient care and outcomes,' Dr. Oern Stuge, executive chairman at OrganOx, said in a statement.

“器官疾病和衰竭在医疗保健领域代表着一个巨大的未满足需求，我们很高兴与HealthQuest Capital及优秀的投资者集团合作，共同努力改善患者护理和治疗效果，”OrganOx执行主席奥恩·斯图格博士在一份声明中表示。

MARKET SNAPSHOT

市场概况

Other companies in the organ disease and transplant space include

其他在器官疾病和移植领域的公司包括

Ubie

乌比

. In 2024, Ubie and the

. 2024年，Ubie和

American Kidney Fund

美国肾脏基金

collaborated to fine-tune Ubie's AI-enabled symptom checker for kidney disease detection with the aim of accelerating a patient's time to treatment.

合作微调了Ubie的AI症状检查器，用于肾脏疾病检测，旨在加快患者的治疗时间。

Through the partnership, AKF would provide 25 to 30 patients who know the cause of their kidney disease to assist Ubie in refining its symptom checker, specifically pertaining to diagnosing kidney disease.

通过合作，AKF将提供25至30名已知肾病病因的患者，协助Ubie改进其症状检查工具，特别是与诊断肾病相关的部分。

In 2023,

2023年，

Strive Health

奋斗健康

announced it signed a

宣布已签署了一项

multiyear deal

多年协议

with

随着

Oak Street Health

橡树街健康中心

, a chain of primary care clinics geared toward the Medicare population to provide care to patients suffering from stage 4 chronic kidney disease to end-stage kidney disease.

，一家面向医疗保险人群的初级保健诊所连锁机构，为患有第四期慢性肾病至终末期肾病的患者提供护理。

Strive Health offers a value-based care platform that integrates chronic kidney disease and end-stage renal disease patient data from various systems into one platform. The platform evaluates disease progression and generates predictions about a patient's condition.

Strive Health 提供了一个基于价值的护理平台，该平台将来自各个系统的慢性肾病和终末期肾病患者数据集成到一个平台中。该平台评估疾病进展并生成有关患者病情的预测。

In 2021, tech-enabled transplant company

2021年，科技赋能的移植公司

CareDx

acquired Transplant Hero, the maker of an app that helps people receiving new organs remember to take their medication.

收购了Transplant Hero，这是一家制作帮助接受新器官移植的人记住服药的应用程序的公司。

CareDx's app, AlloCare, is designed to help patients manage their health post-transplant. According to the company, Transplant Hero's tool aims to build out CareDx's cloud-based products, which cater to patients, dialysis providers and transplant centers.

CareDx的应用程序AlloCare旨在帮助患者管理移植后的健康状况。据该公司称，Transplant Hero的工具旨在完善CareDx基于云的产品，这些产品服务于患者、透析提供商和移植中心。

Tags:

标签：

OrganOx

器官氧

，

medical technology

医学技术

，

organ failure

器官衰竭

，